SG11202109857UA - Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia - Google Patents
Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemiaInfo
- Publication number
- SG11202109857UA SG11202109857UA SG11202109857UA SG11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA SG 11202109857U A SG11202109857U A SG 11202109857UA
- Authority
- SG
- Singapore
- Prior art keywords
- anemia
- antagonists
- treatment
- acetylcholine receptor
- receptor subtype
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202109857UA true SG11202109857UA (en) | 2021-10-28 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202109857U SG11202109857UA (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220185821A1 (en) |
| EP (1) | EP3946321A4 (en) |
| JP (1) | JP2022525293A (en) |
| KR (1) | KR20210144697A (en) |
| CN (1) | CN113613650A (en) |
| AU (1) | AU2020247812A1 (en) |
| BR (1) | BR112021019189A2 (en) |
| CA (1) | CA3132381A1 (en) |
| IL (1) | IL286617A (en) |
| MX (1) | MX2021011588A (en) |
| SG (1) | SG11202109857UA (en) |
| WO (1) | WO2020198054A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6500837B2 (en) * | 2000-09-22 | 2002-12-31 | Warner-Lambert Company | Fused ring system containing indole as M4 selective aza-anthracene muscarinic receptor antagonists |
| EP2036889A4 (en) * | 2006-05-23 | 2009-11-04 | Alla Chem Llc | Substituted indoles and a method for the production and use thereof |
| WO2011113036A2 (en) * | 2010-03-12 | 2011-09-15 | Whitehead Institute For Biomedical Research | Compositions and methods for expanding bfu-e cells |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Drug combinations for protecting against neuronal cell death |
-
2020
- 2020-03-20 US US17/442,926 patent/US20220185821A1/en active Pending
- 2020-03-20 KR KR1020217029823A patent/KR20210144697A/en unknown
- 2020-03-20 AU AU2020247812A patent/AU2020247812A1/en active Pending
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/en unknown
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 JP JP2021553300A patent/JP2022525293A/en active Pending
- 2020-03-20 CN CN202080024089.9A patent/CN113613650A/en active Pending
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en unknown
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/en unknown
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL286617A (en) | 2021-10-31 |
| KR20210144697A (en) | 2021-11-30 |
| WO2020198054A1 (en) | 2020-10-01 |
| JP2022525293A (en) | 2022-05-12 |
| MX2021011588A (en) | 2021-12-15 |
| EP3946321A1 (en) | 2022-02-09 |
| EP3946321A4 (en) | 2023-03-08 |
| AU2020247812A1 (en) | 2021-09-30 |
| CN113613650A (en) | 2021-11-05 |
| BR112021019189A2 (en) | 2021-11-30 |
| US20220185821A1 (en) | 2022-06-16 |
| CA3132381A1 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273924A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL274062A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL276411A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL271805A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP3697781C0 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| CL2007003155A1 (en) | COMPOUNDS DERIVED FROM 3,7-DIAZABICICLO [3.3.0] OCTANO OR 3,7-DIAZABICICLO [3.3.1] NONANO, NEURONAL NICOTINIC RECEIVER MODULATORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CNS DISORDERS. | |
| AP2007004095A0 (en) | Cxcr4 antagonists for the treatment of hiv infection | |
| EP2296658A4 (en) | Nmda receptor antagonists for the treatment of neuropsychiatric disorders | |
| HK1146596A1 (en) | Use of lingo-4 antagonists in the treatment of conditions involving demyelination lingo-4 | |
| ZA202007986B (en) | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor | |
| WO2016066634A3 (en) | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer | |
| EP3732163A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL291029A (en) | Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use | |
| JP2019535799A5 (en) | ||
| EP4041770A4 (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| IL272952A (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| PL3522904T3 (en) | Liquid composition for use in the treatment of gastroesophageal reflux | |
| EP3600289A4 (en) | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | |
| EP3810614C0 (en) | Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| EP4037677A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| GB201802307D0 (en) | CD36 antagonists for use in melanoma treatment | |
| IL288010A (en) | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies | |
| MA43825A (en) | DOSAGE SCHEDULES FOR THE TREATMENT OF FUNGAL INFECTIONS | |
| EP3846806A4 (en) | Muscarinic acetylcholine m1 receptor antagonists | |
| WO2009080351A9 (en) | Compounds with anti-emetic effect |